Argenx SE (ARGX) Gets Upgraded to Buy From Hold at Deutsche Bank

Argenx SE (NASDAQ:ARGX) is one of the most profitable biotech stocks to invest in now. On July 8, Deutsche Bank analyst Emmanuel Papadakis upgraded Argenx SE (NASDAQ:ARGX) to Buy from Hold with a EUR 550 price target.

Is argenx SE (ARGX) the Best Cancer Stock to Invest in for Long-Term Gain?

A lab setting filled with scientific equipment and researchers in lab coats working together to develop new therapies for autoimmune diseases.

Argenx SE (NASDAQ:ARGX) reported that it generated global product net sales of $790 million in Q1 2025, inclusive of both VYVGART and VYVGART SC.

The company also exhibited strong underlying fundamentals across key patient and prescriber metrics, with 99% product net sales growth year-over-year compared to Q1 2024, along with a 7% product net sales growth from Q4 2024.

Argenx SE (NASDAQ:ARGX) is a biotech company that develops treatments for severe autoimmune diseases. The company operates through four segments: the United States, Japan, EMEA, and China.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.